Ginkgo Biloba vs Placebo: What Controlled Trials Show (2026)

The gold standard for evaluating any supplement claim is a randomized, placebo-controlled trial: neither participants nor researchers know who received the real extract until the study ends. Ginkgo has been tested against placebo more than almost any other botanical, and the pattern across those trials is more nuanced than either enthusiastic marketing or blanket dismissal suggests.

Found this useful? Send it to someone who needs it.

This post contains affiliate links. If you buy through them, we may earn a small commission at no extra cost to you. This does not influence what we recommend.

Circulation Trials: A Consistent Edge Over Placebo

Peripheral arterial disease is widely cited as ginkgo’s most reproducible win over placebo. It is not. The Cochrane meta-analysis of 14 randomised trials in 739 participants found the gain in absolute claudication distance fell short of statistical significance (P = 0.06), came to roughly 64 metres on a flat treadmill with a confidence interval that includes no benefit at all, and was probably inflated by publication bias; the reviewers concluded there is no evidence of a clinically significant benefit in peripheral arterial disease[1].

Dementia Trials: Split Results

Some placebo-controlled trials in mild-to-moderate dementia, particularly those using EGb 761 at 240mg/day over 22-24 weeks, showed statistically significant improvement over placebo on cognitive and behavioral rating scales. Others, including large-scale prevention trials like GEM, showed no difference from placebo in preventing cognitive decline in older adults without existing dementia. The split is not random noise, it tracks fairly closely with whether the trial population already had diagnosed cognitive impairment.

Healthy-Adult Cognition: Placebo Often Wins or Ties

In healthy, non-impaired adults, a meaningful number of well-controlled trials found no statistically significant difference between ginkgo and placebo on memory, attention, or processing speed tests. Some smaller or shorter trials found modest effects, but they have not been reliably replicated at scale.

Bronson Ginkgo Biloba Extra Strength Brain & Memory Support 120 Capsules
Bronson Ginkgo Biloba Extra Strength Brain & Memory Support 120 Capsules

Sold as an extra strength brain and memory formula in a 120-count bottle. The memory support wording is label marketing rather than an approved claim, so read the dosage and evidence pages here before deciding what to expect from it.

Capsules120 countExtra strength
Check Price on Amazon › As an Amazon Associate we earn from qualifying purchases.
Editor’s Pick
Nature’s Bounty Ginkgo Biloba 120mg, 100 Capsules
Nature's Bounty Ginkgo Biloba 120mg, 100 Capsules

A plain 120 mg ginkgo capsule in a 100-count bottle from a widely stocked brand. The small count is the point: enough to run a trial of a few weeks and reassess before committing to a larger bottle.

Capsules120 mg100 count
Check Price on Amazon › As an Amazon Associate we earn from qualifying purchases.

Frequently Asked Questions

Why do trial results vary so much across studies?

Differences in extract standardization, dose, trial duration, participant population (healthy vs impaired), and outcome measures used all affect results. Studies using non-standardized extract or shorter than 12 weeks tend to show weaker or no effect.

Does ‘not different from placebo’ mean ginkgo does nothing?

In a specific trial and population, yes, it means the measured effect wasn’t statistically distinguishable from placebo in that context. It doesn’t necessarily generalize to every use case, but it should temper expectations, especially for healthy-adult cognitive enhancement claims.

Which use case has the most reliable placebo-controlled support?

The clearest separation from placebo in the controlled record is not circulation at all. It is symptomatic treatment of people who already have dementia: a meta-analysis of seven randomised placebo-controlled trials of EGb 761 at 120-240 mg/day found significant improvements in cognition, activities of daily living and global rating over 22-26 weeks[2]. Claudication and healthy-adult memory, the two uses ginkgo is marketed for most aggressively, are where placebo-controlled results are weakest.

Important safety note: Ginkgo biloba is often described as a blood thinner. Standardised extract does inhibit platelet aggregation and prolong bleeding time as a pharmacological property[3], but that is a proposed mechanism rather than a confirmed clinical effect: a meta-analysis of 18 randomised trials in 1,985 adults found no significant effect on platelet aggregation, fibrinogen concentration, aPTT or prothrombin time, and did not indicate a higher bleeding risk[4].

A review of controlled studies likewise found that ginkgo did not impair haemostasis or compromise the safety of coadministered aspirin or warfarin, while noting that an idiosyncratic bleeding event cannot be excluded and that isolated case reports do exist[5], including chronic ginkgo use preceding spontaneous subdural haematoma[6].

Those trials were not designed to establish safety in people who are already anticoagulated, so that specific question is open rather than answered. If you take warfarin, aspirin, clopidogrel, or any other blood thinner, or if you have a bleeding disorder or an upcoming surgery, talk to your doctor before starting ginkgo. This applies even to otherwise low-risk uses like memory support.

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

References

  1. Ginkgo biloba for intermittent claudication. Cochrane Database of Systematic Reviews, 2013
  2. Efficacy and tolerability of Ginkgo biloba extract EGb 761 in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clinical Interventions in Aging, 2014
  3. EGb 761: ginkgo biloba extract, Ginkor. Drugs in R&D, 2003
  4. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy, 2011
  5. Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: what is the evidence? Molecular Nutrition & Food Research, 2008
  6. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology, 1996

These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.

Found this useful? Send it to someone who needs it.
Scroll to Top
© 2026 GinkgoHub  |  Health Disclaimer  |  Affiliate Disclosure  |  Privacy Policy  |  Terms  |  About
As an Amazon Associate we earn from qualifying purchases.